ES2160581T3 - Utilizacion de factores de crecimiento similares a la insulina y analogos para el tratamiento del trastorno neuronal retiniano. - Google Patents

Utilizacion de factores de crecimiento similares a la insulina y analogos para el tratamiento del trastorno neuronal retiniano.

Info

Publication number
ES2160581T3
ES2160581T3 ES92924246T ES92924246T ES2160581T3 ES 2160581 T3 ES2160581 T3 ES 2160581T3 ES 92924246 T ES92924246 T ES 92924246T ES 92924246 T ES92924246 T ES 92924246T ES 2160581 T3 ES2160581 T3 ES 2160581T3
Authority
ES
Spain
Prior art keywords
retinian
analogs
treatment
growth factors
similar growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92924246T
Other languages
English (en)
Inventor
Donna Bozyczko-Coyne
Nicola Neff
Michael E Lewis
Mohamed Iqbal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon LLC filed Critical Cephalon LLC
Application granted granted Critical
Publication of ES2160581T3 publication Critical patent/ES2160581T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
    • A01N57/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-carbon bonds
    • A01N57/20—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-carbon bonds containing acyclic or cycloaliphatic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3813—N-Phosphonomethylglycine; Salts or complexes thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Pest Control & Pesticides (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dentistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Agronomy & Crop Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PRESENTA UN METODO PARA PROMOCIONAR LA SUPERVIVENCIA NEURONAL RETINAL EN UN MAMIFERO, EN DONDE LAS CELULAS NEURONALES TIENEN EL RIESGO DE MORIR. EL METODO CONSTA DE LA ADMINISTRACION AL MAMIFERO DE UNA DOSIS EFECTIVA DE AL MENOS UNA DE LAS SIGUIENTES SUSTANCIAS: IGF-I; UN DERIVADO FUNCIONAL DEL IGF-I; IGF-II; O UN DERIVADO FUNCIONAL DEL IGF-II.
ES92924246T 1991-11-08 1992-11-03 Utilizacion de factores de crecimiento similares a la insulina y analogos para el tratamiento del trastorno neuronal retiniano. Expired - Lifetime ES2160581T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79069091A 1991-11-08 1991-11-08
US07/963,329 US6310040B1 (en) 1991-11-08 1992-10-15 Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs

Publications (1)

Publication Number Publication Date
ES2160581T3 true ES2160581T3 (es) 2001-11-16

Family

ID=27121062

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92924246T Expired - Lifetime ES2160581T3 (es) 1991-11-08 1992-11-03 Utilizacion de factores de crecimiento similares a la insulina y analogos para el tratamiento del trastorno neuronal retiniano.

Country Status (9)

Country Link
US (1) US6310040B1 (es)
EP (1) EP0670729B1 (es)
JP (1) JP3445269B2 (es)
AT (1) ATE204176T1 (es)
CA (1) CA2122340C (es)
DE (1) DE69232008T2 (es)
DK (1) DK0670729T3 (es)
ES (1) ES2160581T3 (es)
WO (1) WO1993008826A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
EP0729361A4 (en) * 1993-11-15 1996-11-06 Celtrix Pharma METHOD FOR TREATING NEUROLOGICAL DISEASES
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
WO2001009327A2 (en) * 1999-07-28 2001-02-08 Genentech, Inc. Method of preventing the injury or death of retinal cells and treating ocular diseases
AU3545795A (en) * 1994-09-08 1996-03-27 Chiron Corporation A method of improved production of insulin-like growth factor
JP3191038B2 (ja) * 1996-06-26 2001-07-23 輝夫 西田 眼科用医薬組成物
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
WO1998042369A1 (fr) * 1997-03-24 1998-10-01 Fujisawa Pharmaceutical Co., Ltd. Secretagogues de bile
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
DE60016560T2 (de) 1999-01-06 2005-12-15 Genentech, Inc., South San Francisco Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
AU3737500A (en) * 1999-03-12 2000-09-28 Genentech Inc. Method of preventing the death of retinal neurons and treating ocular diseases
GB9928323D0 (en) * 1999-11-30 2000-01-26 Cyclacel Ltd Peptides
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
DK1282437T3 (da) 2000-05-16 2008-06-30 Genentech Inc Behandling af brusklidelser
WO2001092333A2 (en) * 2000-05-31 2001-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of adnf for enhancing learning and memory
NZ548359A (en) 2001-02-09 2007-11-30 Genentech Inc Method of identifying indirect agonists of insulin-like growth factor-1
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
DE60232880D1 (de) 2001-05-24 2009-08-20 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
TWI305778B (en) 2001-12-03 2009-02-01 Nishida Teruo Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use
JP4253743B2 (ja) * 2001-12-03 2009-04-15 輝夫 西田 新規ペプチドおよびその医薬用途
US20080103457A1 (en) * 2005-01-11 2008-05-01 Heart Failure Technologies, Inc. University Enterprise Laboratories (Uel) Method and System for Treating Heart Failure
US20090054320A1 (en) 2005-04-20 2009-02-26 Protemix Discovery Limited Vesiculins
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
EP1989226A4 (en) * 2006-03-06 2009-11-18 Caregen Co Ltd PEPTIDES HAVING INSULIN-TYPE GROWTH FACTOR ACTIVITY 1 AND USES THEREOF
WO2009070650A1 (en) * 2007-11-26 2009-06-04 The Research Foundation Of State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
EP3272773B8 (en) 2008-05-07 2020-11-18 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
WO2011011072A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1
TWI490371B (zh) 2009-07-28 2015-07-01 Industrie De Nora Spa 電解應用上的電極及其製法以及在電極表面上陽極釋氧之電解法和電冶法
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
CN111763680A (zh) * 2019-05-22 2020-10-13 杭州杰迪生物科技有限公司 一种人胰岛素样生长因子-i或其类似物的制备方法、编码基因、表达载体及宿主细胞

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598205B2 (en) * 1985-08-22 1990-06-21 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
US4783524A (en) 1985-09-17 1988-11-08 Monsanto Company Growth factors
SE8505920D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab New protein and its use
EP0289314B1 (en) 1987-04-28 1994-10-12 Roche Diagnostics GmbH Use of IGF-II in the treatment of bone disorders
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
DE3852636T2 (de) 1987-12-24 1995-05-04 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
ES2101865T3 (es) * 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs

Also Published As

Publication number Publication date
DE69232008D1 (de) 2001-09-20
DE69232008T2 (de) 2001-11-29
DK0670729T3 (da) 2001-12-10
EP0670729A4 (en) 1995-05-10
JPH07500839A (ja) 1995-01-26
EP0670729A1 (en) 1995-09-13
EP0670729B1 (en) 2001-08-16
JP3445269B2 (ja) 2003-09-08
WO1993008826A1 (en) 1993-05-13
CA2122340A1 (en) 1993-05-13
CA2122340C (en) 2007-06-12
ATE204176T1 (de) 2001-09-15
US6310040B1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
ES2160581T3 (es) Utilizacion de factores de crecimiento similares a la insulina y analogos para el tratamiento del trastorno neuronal retiniano.
CA2058443A1 (en) Treating Disorders by Application of Insulin-Like Growth Factors and Analogs
PT671910E (pt) Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma
YU209288A (en) Process for producing compound for treating, which contains azelastin for use in nose and/or eye
HK1030853A1 (en) Transdermal therapeutic device with capsaicin and capsaicin analogs
GR3023613T3 (en) Hepatocyte growth stimulation with hepatocyte growth factor and gamma-interferon.
MY155270A (en) Use of glp-1 or analogs in treatment of stroke
IL83668A (en) Transdermal therapeutic system, its use and process for the production thereof
ATE230986T1 (de) Verwendung von schilddrüsenhormone in ein medizinisches behandlungsverfahren
ES294254U (es) Conjunto de placa de derivacion multiagujas para uso mesoterapico con custodia salvapuntas
DE3851776D1 (de) Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
ATE178801T1 (de) Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
AU587054B2 (en) Novel pharmaceutical compositions intended to the treatment of neuropathies and insuring the nervous regeneration
MX9306043A (es) Utilizacion de il-10 para evitar o tratar diabetes mellitus de pendiente de insulina.
IL143778A0 (en) Transparent transdermal nicotine delivery devices
DE3773893D1 (de) Synergistische kombination von azelastin und theophyllin oder azelastin und beta-mimetika.
ATE108658T1 (de) Verwendung von tetracycline zur herstellung eines arzneimittels zum herabsetzen des augendrucks.
ES2000437T3 (es) Procedimiento para potenciar el crecimiento del parenquima mamario.
MX9206135A (es) Metodos
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
SE9101341D0 (sv) New medicinal use
ES2153828T3 (es) Composiciones que contienen insulina y amilina para el tratamiento de mamiferos deficientes en insulina.
CO5031290A1 (es) Formulacion lo
Kelimbetov et al. Lincomycin concentration in the blood and tissues when administered by electrophoresis in children with acute and chronic hematogenic osteomyelitis
RU92005106A (ru) Способ лечения сахарного диабета

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 670729

Country of ref document: ES